ACTIVE

Idealpharma

Export PDF

Financial year 2025 · closed on 31/12/2025

Net result

-193,4 k €

-1126.0% YoY

Gross margin

6,2 k €

-87.0% YoY

Equity

55,5 k €

-77.7% YoY

What does Idealpharma do?

Idealpharma is a Private company with limited liability incorporated in 2004. Its main activity is: Dispensing chemist in specialised stores. Its registered office is in Antwerpen.

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0864.605.936

Incorporation

08/04/2004

Legal form

Private company with limited liability

Registered office

Heidestraat 1
2660 Antwerpen · FlandreSee on map

Contributed capital

19 000,00 €

Latest accounts

31/12/2025

Activities (NACE)

47730Dispensing chemist in specialised stores· main 47730Dispensing chemist in specialised stores 52310Warehousing and support activities for transportation

Joint committees (1)

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 20 financial years

	2025		2024		2023		2022		2021		2020		2019		2018		2017		2016		2015		2014		2013		2012		2011		2010		2009		2008		2007		2006
Income statement
Gross margin	6,2 k €	-87.0%	47,7 k €	-73.1%	177 k €	-14.2%	206,2 k €	+106%	100,1 k €	-12.1%	113,8 k €	-56.8%	263,7 k €	+66.6%	158,3 k €	-7.2%	170,5 k €	+0.8%	169,1 k €	+6.3%	159 k €	+7.7%	147,7 k €	+2.0%	144,8 k €	+17.5%	123,2 k €	+37.4%	89,7 k €	+80.3%	49,8 k €	-54.3%	108,8 k €	-6.3%	116,1 k €	-18.5%	142,5 k €	+29.1%	110,4 k €
EBITDA	-131,1 k €	-408%	42,6 k €	-75.9%	176,7 k €	-10.2%	196,8 k €	+97.4%	99,7 k €	-12.0%	113,3 k €	-57.0%	263,1 k €	+66.8%	157,8 k €	-7.1%	169,8 k €	+0.8%	168,4 k €	+6.3%	158,5 k €	+7.9%	146,9 k €	+2.0%	143,9 k €	+21.1%	118,9 k €	+33.7%	88,9 k €	+99.4%	44,6 k €	-22.0%	57,2 k €	-18.8%	70,4 k €	-15.8%	83,6 k €	+52.6%	54,8 k €
Operating result	-148,2 k €	-1352%	11,8 k €	-91.9%	146,2 k €	-11.3%	164,9 k €	+144%	67,7 k €	-15.5%	80,1 k €	-64.3%	224,3 k €	+88.8%	118,8 k €	-9.4%	131,2 k €	+2.3%	128,3 k €	+1.2%	126,7 k €	+34.2%	94,4 k €	+2.3%	92,3 k €	+30.6%	70,6 k €	+90.2%	37,1 k €	+592%	-7,5 k €	-199%	7,6 k €	-62.7%	20,5 k €	-38.3%	33,2 k €	+566%	5 k €
Net result	-193,4 k €	-1126%	-15,8 k €	-772%	2,3 k €	-79.9%	11,7 k €	-0.7%	11,8 k €	-69.7%	38,9 k €	-76.8%	168 k €	+96.6%	85,4 k €	-5.0%	89,9 k €	-2.3%	92 k €	+1.7%	90,5 k €	+59.9%	56,6 k €	+3.3%	54,8 k €	+31.6%	41,7 k €	+727%	5 k €	+115%	-33,8 k €	-356%	-7,4 k €	-411%	2,4 k €	-81.2%	12,7 k €	+176%	-16,6 k €
Balance sheet
Equity	55,5 k €	-77.7%	248,9 k €	-6.0%	264,7 k €	+0.9%	262,3 k €	+4.7%	250,6 k €	+4.9%	238,8 k €	+19.5%	199,9 k €	+51.6%	131,9 k €	+23.9%	106,5 k €	+39.1%	76,5 k €	+72.0%	44,5 k €	+219%	14 k €	+627%	-2,6 k €	+88.2%	-22,5 k €	+54.3%	-49,1 k €	+9.3%	-54,2 k €	-108%	-26,1 k €	-39.7%	-18,7 k €	+11.3%	-21,1 k €	+37.5%	-33,7 k €
Total assets	804,5 k €	-18.1%	982,7 k €	-4.2%	1 M €	+1.5%	1 M €	+4.5%	967,2 k €	+33.2%	725,9 k €	-3.0%	748,1 k €	+4.9%	713,5 k €	+6.1%	672,4 k €	+0.9%	666,7 k €	+19.4%	558,3 k €	-5.7%	592,1 k €	+3.4%	572,5 k €	+1.2%	565,6 k €	+9.0%	518,9 k €	-10.9%	582,4 k €	+11.4%	522,8 k €	-9.0%	574,6 k €	-6.3%	613,2 k €	+2.6%	597,7 k €
Cash	7 k €	-21.4%	9 k €	-59.7%	22,2 k €	-14.2%	25,9 k €	+20.8%	21,5 k €	+720%	2,6 k €	-88.9%	23,5 k €	+71.0%	13,8 k €	+139%	5,7 k €	-57.3%	13,5 k €	+243%	3,9 k €	-75.2%	15,8 k €	+334%	3,6 k €	-18.1%	4,5 k €	-72.3%	16,1 k €	-55.7%	36,3 k €	+127%	16 k €	-50.8%	32,6 k €	-43.4%	57,6 k €	+153%	22,8 k €
Debts	749 k €	+2.1%	733,8 k €	-3.6%	760,9 k €	+1.7%	748,3 k €	+4.4%	716,6 k €	+47.1%	487 k €	-11.0%	547,4 k €	-5.7%	580,7 k €	+2.6%	566 k €	-3.6%	587,4 k €	+14.9%	511 k €	-11.0%	574,4 k €	+0.8%	569,7 k €	-2.4%	583,6 k €	+3.7%	563 k €	-10.8%	631,4 k €	+15.0%	548,9 k €	-7.5%	593,3 k €	-6.5%	634,2 k €	+0.4%	631,4 k €
Other
Workforce	–		–		–		–		–		–		–		–		–		–		–		–		–		–		–		–		1,0 ETP	+11.1%	0,9 ETP	-18.2%	1,1 ETP	0.0%	1,1 ETP

Estimate

Indicative valuation

As an indication, this company is worth

between 0 € and 100 k€

See the valuation

Governance

Board of directors

Seen on filing of 31/12/2025 · 2 active · 8 ended

Active mandates

Laurent Cooreman

Director

Active

Marleen Slaets

Director

Active

Ended mandates

E-pharma

Manager · since 01 janvier 2010 · 0821.059.072

Represented by Erik Van Nuffel

Ended

Bart Waelput

Manager

Ended

Catherine Callens

Manager

Ended

E-pharma

Manager · 0821.059.072

Represented by Erik Van Nuffel

Ended

At this address

Other companies at this address

Company	CBE no.
MEDISYNALL● Active	0754.950.208

Annual accounts

Full financial information

	2025	2024	2023	2022	2021	2020
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	28/07/2026	30/09/2025	30/08/2024	05/08/2023	28/07/2022	23/08/2021
General meeting	19/06/2026	20/06/2025	21/06/2024	16/06/2023	17/06/2022	18/06/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

21 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2025	19/06/2026	28/07/2026	Dutch	PDF
Abridged model	31/12/2024	20/06/2025	30/09/2025	Dutch	PDF
Abridged model	31/12/2023	21/06/2024	30/08/2024	Dutch	PDF
Abridged model	31/12/2022	16/06/2023	05/08/2023	Dutch	PDF
Abridged model	31/12/2021	17/06/2022	28/07/2022	Dutch	PDF
Abridged model	31/12/2020	18/06/2021	23/08/2021	Dutch	PDF
Abridged model	31/12/2019	19/06/2020	26/08/2020	Dutch	PDF
Abridged model	31/12/2018	21/06/2019	26/07/2019	Dutch	PDF
Abridged model	31/12/2017	15/06/2018	31/07/2018	Dutch	PDF
Abridged model	31/12/2016	16/06/2017	28/07/2017	Dutch	PDF
Abridged modelCorrection	31/12/2015	17/06/2016	26/09/2016	Dutch	PDF
Abridged model	31/12/2015	17/06/2016	24/07/2016	Dutch	PDF
Abridged model	31/12/2014	19/06/2015	27/07/2015	Dutch	PDF
Abridged model	31/12/2013	20/06/2014	26/07/2014	Dutch	PDF
Abridged model	31/12/2012	21/06/2013	31/07/2013	Dutch	PDF
Abridged model	31/12/2011	15/06/2012	29/07/2012	Dutch	PDF
Abridged model	31/12/2010	17/06/2011	01/08/2011	Dutch	PDF
Abridged model	31/12/2009	18/06/2010	22/06/2010	Dutch	PDF
Abridged model	31/12/2008	27/08/2009	28/08/2009	Dutch	PDF
Abridged model	31/12/2007	29/07/2008	29/08/2008	Dutch	PDF
Abridged model	31/12/2006	15/06/2007	18/07/2007	Dutch	PDF

Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 0 € and 100 k€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 2 active · 8 ended

Active mandates

Laurent Cooreman

Director

Active

Marleen Slaets

Director

Active

Ended mandates

E-pharma

Manager · since 01 janvier 2010 · 0821.059.072

Represented by Erik Van Nuffel

Ended

Bart Waelput

Manager

Ended

Catherine Callens

Manager

Ended

E-pharma

Manager · 0821.059.072

Represented by Erik Van Nuffel

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Mandates18/09/2024
ONTSLAGEN - BENOEMINGEN
PDF
Mandates24/12/2020
ONTSLAGEN - BENOEMINGEN - WIJZIGING RECHTSVORM
PDF
Mandates07/12/2010
ONTSLAGEN - BENOEMINGEN
PDF
Other09/04/2010
DIVERSEN
PDF
Mandates16/02/2010
MAATSCHAPPELIJKE ZETEL - ONTSLAGEN - BENOEMINGEN
PDF
Other21/04/2004
RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2025
Annual accounts 2025-193,4 k €↓
2024
Annual accounts 2024-15,8 k €↓
2023
Annual accounts 20232,3 k €↓
2022
Annual accounts 202211,7 k €↓
2021
Annual accounts 202111,8 k €↓
2020
Annual accounts 202038,9 k €↓
2019
Annual accounts 2019168 k €↑
2018
Annual accounts 201885,4 k €↓
2017
Annual accounts 201789,9 k €↓
2016
Annual accounts 201692 k €↑
2015
Annual accounts 201590,5 k €↑
2014
Annual accounts 201456,6 k €↑
2013
Annual accounts 201354,8 k €↑
2012
Annual accounts 201241,7 k €↑
2011
Annual accounts 20115 k €↑
2010
Annual accounts 2010-33,8 k €↓
2009
Annual accounts 2009-7,4 k €↓
2008
Annual accounts 20082,4 k €↓
2007
Annual accounts 200712,7 k €↑
2006
Annual accounts 2006-16,6 k €
08/04/2004
IncorporationPrivate company with limited liability

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

Idealpharma

Overview

What does Idealpharma do?

Trend over 20 financial years

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline